ArticleCell death & disease2020
Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts.
Article in Cell death & disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 124 citations in OpenAlex.
- Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Trial
- Toxicity of Some Natural Products in the Treatment of Rheumatoid Arthritis.Life (Basel, Switzerland) · 2026Review
- Cannabidiol attenuates chemotherapy-induced peripheral neuropathic pain through a mechanism that requires the enzymebioRxiv : the preprint server for biology · 2026Article
- Toxicity and health effects of delta-8, delta-9, and delta-10-tetrahydrocannabinol and unregulated cannabinoids in vaping products.Toxicology reports · 2026Review
- Cannabinoids in immune system-related diseases: From bench to clinic.Chinese medical journal · 2026Review
- Moderate Dietary Cannabidiol Enhances Growth, Restructures Gut Microbiota, and Bolsters Environmental Stress Resilience inAntioxidants (Basel, Switzerland) · 2026Article
- Exploring the therapeutic potential of cannabidiol in soft tissue wound healing: Delivery strategies and anti-inflammatory pathways.Acta pharmaceutica Sinica. B · 2026Review
- Review
- The development of a cannabis risk assessment tool for patients with rheumatologic conditions: a Delphi study.Clinical rheumatology · 2026Article
- THC and CBD Induce Heme Oxygenase-1-Dependent Cell Death and Trigger Mitochondrial Dysfunction in Human Melanoma and Cutaneous Squamous Cell Carcinoma Cells.Antioxidants (Basel, Switzerland) · 2026Article
- Herbal Formula IM-B Possesses Antioxidant Activities and Reduces Expression of Proinflammatory Cytokines in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages.Scientifica · 2026Article
- Cannabidiol does not cause DNA double-strand breaks in a human liver-derived cell model.Journal of cannabis research · 2025Article
- Natural Powerhouse Duo: Hierarchical Levan Hydrogels with Nanoencapsulated Cannabidiol as Local Delivery Systems.Pharmaceutical research · 2025Article
- The effects of Cannabidiol on podocytes in vitro.Biochemical and biophysical research communications · 2025Article
- Cannabis Derivatives as Ingredients of Functional Foods to Combat the COVID-19 Pandemic.Foods (Basel, Switzerland) · 2025Review
- Multiple intramolecular triggers converge to preferential G protein coupling in the CBNature communications · 2025Article
- The Protective Effect of Nimodipine in Schwann Cells Is Related to the Upregulation of LMO4 and SERCA3 Accompanied by the Fine-Tuning of Intracellular Calcium Levels.International journal of molecular sciences · 2025Article
- Current and Potential Use of Biologically Active Compounds Derived fromInternational journal of molecular sciences · 2024Review
- High-CBD Extract (CBD-X) in Asthma Management: Reducing Th2-Driven Cytokine Secretion and Neutrophil/Eosinophil Activity.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Association between cannabis use and physical activity in the United States based on legalization and health status.Journal of cannabis research · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabidiol (CBD) is a non-intoxicating phytocannabinoid from cannabis sativa that has demonstrated anti-inflammatory effects in several inflammatory conditions including arthritis. However, CBD binds to several receptors and enzymes and, therefore, its mode of action remains elusive. In this study, we show that CBD increases intracellular calcium levels, reduces cell viability and IL-6/IL-8/MMP-3 production of rheumatoid arthritis synovial fibroblasts (RASF). These effects were pronounced under inflammatory conditions by activating transient receptor potential ankyrin (TRPA1), and by opening of the mitochondrial permeability transition pore. Changes in intracellular calcium and cell viability were determined by using the fluorescent dyes Cal-520/PoPo3 together with cell titer blue and the luminescent dye RealTime-glo. Cell-based impedance measurements were conducted with the XCELLigence system and TRPA1 protein was detected by flow cytometry. Cytokine production was evaluated by ELISA. CBD reduced cell viability, proliferation, and IL-6/IL-8 production of RASF. Moreover, CBD increased intracellular calcium and uptake of the cationic viability dye PoPo3 in RASF, which was enhanced by pre-treatment with TNF. Concomitant incubation of CBD with the TRPA1 antagonist A967079 but not the TRPV1 antagonist capsazepine reduced the effects of CBD on calcium and PoPo3 uptake. In addition, an inhibitor of the mitochondrial permeability transition pore, cyclosporin A, also blocked the effects of CBD on cell viability and IL-8 production. PoPo3 uptake was inhibited by the voltage-dependent anion-selective channel inhibitor DIDS and Decynium-22, an inhibitor for all organic cation transporter isoforms. CBD increases intracellular calcium levels, reduces cell viability, and IL-6/IL-8/MMP-3 production of RASF by activating TRPA1 and mitochondrial targets. This effect was enhanced by pre-treatment with TNF suggesting that CBD preferentially targets activated, pro-inflammatory RASF. Thus, CBD possesses anti-arthritic activity and might ameliorate arthritis via targeting synovial fibroblasts under inflammatory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.